Teriflunomide (Aubagio, Genzyme/Sanofi) is coming into the MS market . It is an oral drug, nice.
“30% lower than the rate for those taking a placebo,” said Russell Katz, MD,” What does that mean?
Maybe not as clear as just a percent reduction in releases, think compounding. Sagepub has an article  discussing this topic. One thing is for sure you need all the intimate details of a study to know what was really measured. After several years the number of relapses may have fallen by a much greater amount than 30% mentioned. The efficacy of RRMS Drugs (Relapsing Remitting Multiple Sclerosis) is measured in how well it decreases the annualized relapse rates (ARR).
Such rates are subject to interpretation and statistical manipulation.
Quoting  :
“…Out of the 72 randomized control trials, 56 (77.8%) articles had deﬁned relapse or exacerbation, while 17 (23.7%) did not deﬁne the term relapse or exacerbation. Of these 56 articles, the study population consisted of 37 (66.1%) with RRMS, 8 (14.3%) were either RRMS or SPMS, and 11 (19.6%) involved other or unknown MS categories…”
The patient taking Aubagio has to accept the following liver risks:
“…A boxed warning will alert prescribers to the risk for liver problems, including death, and a risk for birth defects with use of teriflunomide. “Physicians should do blood tests to check liver function before a patient starts taking Aubagio, and periodically during treatment,” the FDA statement notes…”
Technically, this is how Aubagio works:
“…Teriflunomide is a once-daily oral immunomodulator developed as a disease-modifying therapy for MS. It reversibly inhibits …a key mitochondrial enzyme involved in pyrimidine synthesis for DNA replication. As a result, the drug reduces T- and B-cell proliferation and function in response to autoantigens but preserves the replication and function of cells
- Mitochondrion : membrane-enclosed organelle, or mini organ, at the cellular level